Ads
related to: body systems affected by copd and asthma treatment drugs summarytopdealweb.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Pulmonary drug delivery is mainly utilized for topical applications in the lungs, such as the use of inhaled beta-agonists, corticosteroids and anticholinergic agents for the treatment of asthma and COPD, the use of inhaled mucolytics and antibiotics for the treatment of cystic fibrosis (CT) and respiratory viral infections, [1] and the use of inhaled prostacyclin analogs for the treatment of ...
They are primarily used to treat asthma and other pulmonary disorders. Bronchodilators are considered an important treatment regime for chronic obstructive pulmonary disease (COPD) and are usually used in combination with short acting medications and long acting medications in a combined inhaler. [1] [2]
Bronchodilators may be originating naturally within the body, or they may be medications administered for the treatment of breathing difficulties, usually in the form of inhalers. They are most useful in obstructive lung diseases, of which asthma and chronic obstructive pulmonary disease are the most common conditions.
When combined with inhaled steroids, β adrenoceptor agonists can improve symptoms. [1] [2] In children this benefit is uncertain and they may be potentially harmful. [2]They should not be used without an accompanying steroid due to an increased risk of severe symptoms, including exacerbation in both children and adults. [3]
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
This long duration of action made the treatment for severe asthma and COPD more convenient for the patients because it is inhaled twice a day. [1] In 2013 an extra long-acting β 2-agonist, vilanterol, was marketed. Its duration of action lasts for 24 hours which should improve patients' compliance and make the treatment more convenient. [2]
Ads
related to: body systems affected by copd and asthma treatment drugs summarytopdealweb.com has been visited by 10K+ users in the past month